JPWO2020132456A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020132456A5
JPWO2020132456A5 JP2021536271A JP2021536271A JPWO2020132456A5 JP WO2020132456 A5 JPWO2020132456 A5 JP WO2020132456A5 JP 2021536271 A JP2021536271 A JP 2021536271A JP 2021536271 A JP2021536271 A JP 2021536271A JP WO2020132456 A5 JPWO2020132456 A5 JP WO2020132456A5
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536271A
Other languages
English (en)
Japanese (ja)
Other versions
JP7614647B2 (ja
JP2022515226A (ja
JP2022515226A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067874 external-priority patent/WO2020132456A1/en
Publication of JP2022515226A publication Critical patent/JP2022515226A/ja
Publication of JPWO2020132456A5 publication Critical patent/JPWO2020132456A5/ja
Publication of JP2022515226A5 publication Critical patent/JP2022515226A5/ja
Application granted granted Critical
Publication of JP7614647B2 publication Critical patent/JP7614647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021536271A 2018-12-20 2019-12-20 １型糖尿病、その他の自己免疫疾患の処置 Active JP7614647B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862782646P 2018-12-20 2018-12-20
US201862782624P 2018-12-20 2018-12-20
US62/782,624 2018-12-20
US62/782,646 2018-12-20
US201962854289P 2019-05-29 2019-05-29
US201962854286P 2019-05-29 2019-05-29
US62/854,289 2019-05-29
US62/854,286 2019-05-29
PCT/US2019/067874 WO2020132456A1 (en) 2018-12-20 2019-12-20 Treating type 1 diabetes, other autoimmune diseases

Publications (4)

Publication Number Publication Date
JP2022515226A JP2022515226A (ja) 2022-02-17
JPWO2020132456A5 true JPWO2020132456A5 (https=) 2023-01-11
JP2022515226A5 JP2022515226A5 (https=) 2023-01-11
JP7614647B2 JP7614647B2 (ja) 2025-01-16

Family

ID=71101601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536271A Active JP7614647B2 (ja) 2018-12-20 2019-12-20 １型糖尿病、その他の自己免疫疾患の処置

Country Status (4)

Country Link
US (1) US20220073963A1 (https=)
EP (1) EP3899039A4 (https=)
JP (1) JP7614647B2 (https=)
WO (1) WO2020132456A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060125916A (ko) 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 자가면역 질병을 치료하기 위한 방법 및 조성물
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法
EP4219759A3 (en) 2010-05-06 2023-09-06 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
EP3134132B1 (en) 2014-04-22 2019-07-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
WO2016100615A2 (en) 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza

Similar Documents

Publication Publication Date Title
ES2848052T3 (es) Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
ES2765874T3 (es) Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
TW202043280A (zh) 對受體酪胺酸激酶樣孤兒受體１（ｒｏｒ１）具專一性之抗體及嵌合抗原受體
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
TW201938203A (zh) 靶向共有抗原之抗原結合蛋白
SA518390904B1 (ar) مستقبلات مولد مضاد خيمرية تقوم على أجسام مضادة أحادية الحقل وطرق لاستخدامها
KR20190141211A (ko) Cd19에 대한 인간화 항원-결합 도메인 및 사용 방법
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
IL320680A (en) Antigen-binding proteins targeting shared antigens
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20220115572A (ko) 항-b7-h3 단클론성 항체 및 이의 사용 방법
KR20220042128A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
US20230128075A1 (en) Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
KR20220042131A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-lrrc25 조성물 및 방법, 그리고 이의 용도
JP7614647B2 (ja) １型糖尿病、その他の自己免疫疾患の処置
CN120035444A (zh) 针对psma的亲和结合实体及其使用方法
WO2026085531A1 (en) Compositions and methods for treating or preventing type 1 diabetes and other autoimmune diseases
JPWO2020132456A5 (https=)
Wang Application of Anti-CD3 Immunoglobulins to Study TCR/CD3 Triggering Mechanisms